Stockscreener 앱 받기
53.30
2.56%
-1.40
시간 외 거래:
58.80
5.50
+10.32%
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
Nektar Therapeutics (Nasdaq: NKTR) to review 36-week REZOLVE-AA topline data Dec. 16 - Stock Titan
Transformative Advances This Year and Beyond - Dermatology Times
Nektar Therapeutics (NASDAQ:NKTR) Stock Price Up 11%Here's Why - MarketBeat
Rezpegaldesleukin Shows Promise for AD, Comorbid Asthma, With Jonathan Corren, MD - HCPLive
Published on: 2025-12-14 04:41:07 - moha.gov.vn
Nektar Therapeutics (NASDAQ:NKTR) Trading Down 5.5%Here's What Happened - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 5.5%What's Next? - MarketBeat
Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation - MSN
Can Nektar Therapeutics Stock Recover If Markets Fall? - Trefis
Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy - sharewise.com
Nektar Therapeutics $NKTR Shares Sold by 22NW LP - MarketBeat
Is Nektar Therapeutics (NKTR) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance
Nektar Therapeutics gains amid takeover speculation - MSN
Nektar Therapeutics (NKTR) Price Target Increased by 14.31% to 109.43 - Nasdaq
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Stonepine Capital Management LLC Makes New Investment in Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $102 - 富途牛牛
Will Nektar Therapeutics stock maintain dividend yieldOptions Play & Real-Time Volume Trigger Notifications - Newser
Can Nektar Therapeutics (ITH0) stock stage a strong rebound this quarterPortfolio Performance Summary & Weekly High Return Stock Opportunities - Newser
Will Nektar Therapeutics stock benefit from green energy trendsTrade Signal Summary & Daily Oversold Stock Bounce Ideas - Newser
How robust is Nektar Therapeutics (ITH0) stock financial positionAnalyst Upgrade & Risk Controlled Daily Trade Plans - Newser
How strong dollar benefits Nektar Therapeutics (ITH0) stockTrade Risk Assessment & Long-Term Safe Investment Ideas - Newser
NKTR SEC FilingsNektar Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Will Nektar Therapeutics stock benefit from upcoming earnings reports2025 Top Gainers & Verified Momentum Stock Alerts - Newser
Is Nektar Therapeutics stock attractive for ETFs2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 7.5%What's Next? - MarketBeat
Colorectal Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeu - Barchart.com
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - The Manila Times
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - GlobeNewswire Inc.
Latex Allergy Market Covering Prime Factors and Competitive - openPR.com
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade - Finviz
Nektar Therapeutics Reveals Promising Phase 2b Trial Results - MSN
Nektar Therapeutics (NKTR) Stock Forecasts - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap UpShould You Buy? - MarketBeat
Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Jefferies Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq
Citigroup Initiates Coverage on NKTR with 'Buy' Rating | NKTR St - GuruFocus
Jefferies Raises Nektar Therapeutics (NKTR) Price Target to $121 - GuruFocus
Nektar Therapeutics R (ITH0.MU) Q2 FY2025 earnings call transcript - Yahoo Finance
Nektar Therapeutics CEO sells $119,795 in shares By Investing.com - Investing.com South Africa
Citi starts Nektar with Buy, opens ‘positive catalyst watch’ - TipRanks
Nektar (NKTR) Receives Buy Rating with Positive Outlook from Cit - GuruFocus
Citi Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Portland Topic NEKTAR THERAPEUTICS | News, Weather, Sports, Breaking News - KATU
Jefferies Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $121 - 富途牛牛
Nektar Therapeutics chief R&D officer sells $62,801 in stock By Investing.com - Investing.com Australia
Nektar Therapeutics CLO Wilson sells $34,196 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire) - Aktiellt
Nektar Therapeutics chief R&D officer sells $62,801 in stock - Investing.com
Nektar Therapeutics CLO Wilson sells $34,196 in shares - Investing.com
0.36%
1.05%
자본화:
|
볼륨(24시간):